Recent Updates — BOLT
Bolt Biotherapeutics completed its acquisition of Prana Therapies via a reverse merger, issuing 430,746 shares of common stock and 16,360.929 shares of Series D convertible preferred stock to former Prana shareholders. Concurrently, Bolt raised $120 million in gross proceeds through the private placement of Series D preferred stock and warrants, with potential for an additional $60 million upon warrant exercise. Dr. Sheila Gujrathi, Prana's co-founder and former CEO, joined Bolt's board as a Class II director and was appointed Chief Strategy Officer. The combined company will advance PRA-216, a bispecific antibody in Phase 2 development for inflammatory diseases. Bolt Biotherapeutics is a clinical-stage biotechnology company developing multispecific antibodies.
Bolt Biotherapeutics entered into a Second Amendment to Lease with landlord HCP LS Redwood City LLC, paying $1.0 million upfront and allowing the landlord to draw on an existing $1.5 million letter of credit. The amendment accelerates the lease expiration to December 31, 2027, or earlier upon the closing of a financing or strategic transaction. If such a corporate transaction closes, Bolt Bio must pay an additional $4.5 million termination fee. Ongoing rent obligations are no longer significant as the company maintains sublease arrangements for portions of its facilities. The company is evaluating the accounting effects of this agreement. Bolt Biotherapeutics operates in the biotechnology industry, focusing on developing therapies to treat cancer and other diseases.
Bolt Biotherapeutics reported financial results for the second quarter ended June 30, 2026. The company generated collaboration revenue of $5,000 and incurred a net loss of $7.7 million. Operating expenses decreased to $8.4 million from $9.2 million in the prior year period due to restructuring and lower research activities. Cash and marketable securities totaled $18.1 million as of June 30, 2026, which management anticipates will fund operations into the first quarter of 2027. Clinically, the Phase 1/2 study for BDC-4182 in gastric and gastroesophageal cancer is ongoing with patients treated in Cohort 4 at 4.0 mg/kg; initial clinical data is expected with third-quarter results. Bolt Biotherapeutics operates as a clinical-stage biopharmaceutical company developing novel immunotherapies, specifically immune-stimulating antibody conjugates, for the treatment of cancer.